Doctors prescribe less PPI medications now

Following a study which proved that PPIs cause calcium malabsorption many doctors reduced number of prescriptions for PPIs they give to patients. According to recent studies people who take PPIs for a long period of time have increased risk of fractures. This is caused by the fact that PPI drugs significantly decrease level of acid in this stomach which in its turn decrease levels of calcium absorption. Before these studies PPIs were generally considered by doctors as completely safe drugs without significant side effects and were prescribed pretty much in most acid reflux related cases.

Following prescription drugs are part of PPI family: Nexium, Dexilant, Prilosec, Zegerid, Prevacid, Protonix, and Aciphex. OTC brands include Prilosec OTC, Zegerid OTC and Prevacid 24HR.

Recent studies covering patients 50 years or older found that those who took PPIs for periods longer than 1 year have increased risk of hip, wrist, spine and other osteoporotics fractures. Before the studies doctors thought that fractures were caused by different reasons like age and postmenopausal osteoporosis. But based on the results this is not the case.
Thus be cautious when taking PPI drugs – don’t use them for prolonged period of time especially if there is no real need for it. Try to replace it with wedge pillow and diet. This combination may significantly reduce need for PPIs.

 

Endogastric Solutions raises $30m in Series F financing round

Endogastric Solutions based in Redwood City, CA reported today that it raised $30m in Series F financing from Canaan Partners and Radius Ventures together with Advanced Technology Ventures, MPM Capital, Foundation Medical Partners, Chicago Growth Partners, and De Novo Ventures.
Endogastric Solutions develops and markets devices for NOS (Natural Orifice Surgery) which is the next step in evolution of minimally invasive surgery. Key procedure performed with NOS is EsophyX – which fixes GERD and Hiatal Hernia through incisionless surgery. It uses an EsophyX device which is inserted through patient mouth and under visual guidance of endoscope creates a barrier to reflux and restores function of gastroesophageal junction.
This procedure was already performed on more than a thousand patients worldwide and results are very promision. Two year follow up shows that 85% patients are still heartburn free and 79% stay off daily PPIs.
There is a significant market for this procedure since 20-40% of 30 million Americans diagnosed with GERD are not satisfied with PPI therapy. Also according to recent studies long term PPI therapy could lead to osteomalacia (inadequate absorption of calcium and other minerals into the bones).
Another procedure developed by Endogastric Solutions is StomaphyX which is used for transoral tissue approximation, ligation and full-thickness plication in the GI tract.
We hope that EsophyX will pass the test of time and will become safe solution for patients who want to get away from pharmaceutical treatment. At this moment procedure is already FDA approved and could be performed by qualified doctors in your area.